

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,132,530 B2
APPLICATION NO. : 10/633843
DATED : November 7, 2006
INVENTOR(S) : C. Frank Bennett and Kenneth Dobie

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On title page, item (56), References Cited, OTHER PUBLICATIONS, right hand column, Alisky et al. reference, please delete "laterial" and insert therefore
--lateral--

On title page, item (74), Attorney, Agent, or Firm, please delete "Knobbe Martens Olson & Bear LLP" and insert therefore --Isis Pharmaceuticals, Inc. Patent Department and Knobbe Martens Olson & Bear LLP--

On title page 2, OTHER PUBLICATIONS, left hand column, Trott et al. reference, please delete "SODI" and insert therefore --SOD1--

Column 9, line 18, please delete "-CH₂-O-N(CH₃) -CH₂," and insert therefore
--CH₂-O-N(CH₃)-CH₂--

Column 9, line 34, please delete "O(CH₂)_nCH₃" and insert therefore
--O(CH₂)_nCH₃--

Column 9, line 61, please delete "(-CH₂-)_n" and insert therefore --(-CH₂-)_n--

Column 20, line 16, please delete "(S0750)" and insert therefore --(SO750)--

Column 20, line 17, please delete "(DA0750)" and insert therefore
--(DAO750)--

Column 29, line 47, please delete "2' -deoxy-21-fluoroadenosine" and insert therefore --2'-deoxy-2' - fluoroadenosine--

Column 31, line 17, please delete "2'-O-Methoxyethyl-51-O-dimethoxytrityl-5-methyluri-" and insert therefore --2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluri--

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,132,530 B2
APPLICATION NO. : 10/633843
DATED : November 7, 2006
INVENTOR(S) : C. Frank Bennett and Kenneth Dobie

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 32, line 23, please delete "L) Tetrazole" and insert therefore --L).

Tetrazole--

Column 35, line 41, please delete "bamoyl-2¹-O-([2-phthalmidoxy]ethyl)-5'-O-(4,4'-' and insert therefore --bamoyl-2'-O-([2-phthalmidoxy]ethyl]-5'-O-(4,4'--

Column 36, line 65, please delete "31-Deoxy-3'-amino" and insert therefore
--3'-Deoxy-3'-amino--

Column 40, line 48, please delete "TCCGTCATCGCTCCTCAGGG" and insert therefore --TCCGTCATCGCTCCTCAGGG--

Column 40, lines 52-53, please delete "ATGCATTCTGCCCAAGGA" and insert therefore --ATGCATTCTGCCCAAGGA--

Column 41, line 12, please delete "poly(A)+mRNA" and insert therefore
--poly(A)+ mRNA--

Column 41, line 56, please delete "Poly(A)+mRNA" and insert therefore
--Poly(A)+ mRNA--

Column 41, line 57, please delete "Poly(A)+mRNA" and insert therefore
--Poly(A)+ mRNA--

Column 41, line 59, please delete "poly(A)+mRNA" and insert therefore
--poly(A)+ mRNA--

Column 43, line 52, please delete "MULV" and insert therefore --MuLV--

Column 87, Claim 9, line 43, please delete "chiracric" and insert therefore
--chimeric--

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,132,530 B2
APPLICATION NO. : 10/633843
DATED : November 7, 2006
INVENTOR(S) : C. Frank Bennett and Kenneth Dobie

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 88, Claim 13, line 24, please delete "NO;3)" and insert therefore


--NO:3)--

Column 88, Claim 13, line 25, after "SEQ ID NO. 15" please insert --, wherein
said antisense compound is an antisense oligonucleotide,--

Column 88, Claim 22, lines 46-47, please delete "**22.** The composition of claim
20 wherein the compound is an antisense oligonucleotide."

Signed and Sealed this

Eleventh Day of September, 2007



JON W. DUDAS
Director of the United States Patent and Trademark Office